Results of multi-centre monitoring of sibutramine treatment in obese diabetic patients in Czech Republic


Authors: A. Šmahelová
Authors‘ workplace: Klinika gerontologická a metabolická Lékařské fakulty UK a FN, Hradec Králové, přednosta prof. MUDr. Luboš Sobotka, CSc.
Published in: Vnitř Lék 2005; 51(6): 676-680
Category: Original Contributions

Overview

Sibutramine is a very effective antiobesitic drug in the present. It has weight reducing, global metabolic and antidiabetic effects. To verify and to get the experiences with practical use of sibutramin in Type 2 diabetics in the Czech Republic was the purpose of the clinical observation MERIDIOS I.

Patients and methods:
499 diabetics (average age 52.4 ± 9,5 years) were included, to the statistical evaluation after 3 months of the therapy Wilcoxon rank sum test was used. 308 (61,7%) diabetics took oral antidiabetic agents. 424 (83%) diabetics used antihypertensive drugs, 384 (75%) hypolipidemic agents. 275 (55.1%) diabetics took sibutramine in the dose 10 mg once a day, 224 (44.9%) diabetics in the dose 15 mg once a day.

Results:
The average weight loss was 6.1 kg (p < 0.001). Waist circumference diminished about 4.7 cm (p < 0.001), glycosylated hemoglobin about 0.75% (p < 0.001), systolic blood pressure about 5.2 mm Hg (p < 0.001), diastolic blood pressure about 3.1 mm Hg (p < 0.001) in average. The daily dosage of oral antidiabetic agents diminished in 33.1% of all included diabetics. Any serious adverse events of sibutramine were recorded.

Conclusion:
Significant weight loss, diminished waist circumference and blood pressure, improvement of diabetes compensation and lower daily dose of oral hypoglycemic agents were observed in obese Type 2 diabetics after 3 months therapy with sibutramine in the dose 10 or 15 mg per day.

Key words:
diabetes mellitus type 2 – sibutramin – obesity


Sources

1. Avenell A, Brown TJ, McGee MA et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic reviw of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet 2004; 17: 293–316.

2. Svačina Š, Owen K. Obezita, diabetes 2. typu a jejich kvantitativní vztahy. Vnitř Lék 2002; 48: 500–506.

3. Atkinson RL. Clinical guidelines on the indentification, evaluation, and pharmacologic treatment of obesity in adults. Endotext Com 2003; 25: Ch 15b.

4. Fujioka K, Seaton TB, Rowe E et al. Weight loss with sibutramine improves glycemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000; 2: 175–187.

5. Gokcel A, Karakose H, Ertorer EM et al. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 2001; 24: 1957–1960.

6. Derosa G, Cicero AF G et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Nutr Metab 2004; 17: 222–229.

7. Goldstein BJ, Muller–Wieland D. Textbook of Type 2 Diabetes. London: Martin Dunitz 2003.

8. Hauner H, Meier M, Wendland G et al. SAT Study. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT study. Exp Clin Endocrinol Diabetes 2004; 112: 201–207.

9. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). Brit Med J 1998; 317: 703–713.

10. Van Gaal LF, Wauters MA, Peiffer FW et al. Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? Int J Obesity 1998; 22(Suppl 1): S38–S40; discussion S41–S42.

11. McNulty SJ, Williams GA. Randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003; 26: 125–131.

12. Serrano-Rios M, Melchionda N, Moreno-Carretero E. Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy. Diabet Med 2002; 19: 119–124.

Labels
Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

Issue 6

2005 Issue 6

Most read in this issue
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account